Weijian Sun
Impact in
- Cancer Research top 10%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Biomaterials top 5%
- Nanoparticle-Based Drug Delivery
Papers in
-
- Extracellular vesicles in disease 5
- Histone Deacetylase Inhibitors Research 4
- RNA modifications and cancer 4
-
- Nanoplatforms for cancer theranostics 16
- 3D Printing in Biomedical Research 7
- Innovative Microfluidic and Catalytic Techniques Innovation 6
- Co-authors
- Xian Shen (23 shared papers)Mingdong Lu (15 shared papers)Yuanjin Zhao (10 shared papers)Pihong Li (10 shared papers)Zhiqiang Zheng (11 shared papers)Qingfei Zhang (10 shared papers)Yongdong Yi (11 shared papers)Hui Zhang (2 shared papers)
- Journals
- Chemical Engineering Journal (6 papers)International Journal of Biological Macromolecules (4 papers)Advanced Science (4 papers)OncoTargets and Therapy (2 papers)BMC Cancer (2 papers)
- Partner nations
- ChinaUnited StatesSingapore
In The Last Decade
Weijian Sun
79 papers receiving 1.6k citations
Hit Papers
Peers
Comparison fields: 5 of 122
- Cancer Research 274
- Biomaterials 195
- Molecular Medicine 62
- Biomedical Engineering 482
- Molecular Biology 719
Countries citing papers authored by Weijian Sun
This map shows the geographic impact of Weijian Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weijian Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weijian Sun more than expected).
Fields of papers citing papers by Weijian Sun
This network shows the impact of papers produced by Weijian Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weijian Sun. The network helps show where Weijian Sun may publish in the future.
Co-authors
The 25 scholars most cited alongside Weijian Sun, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 84 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 97 | |
| 2 | Elesclomol Loaded Copper Oxide Nanoplatform Triggers Cuproptosis to Enhance Antitumor Immunotherapy Hit paper breakdown → | 2024 | 93 |
| 3 | 2022 | 76 | |
| 4 | 2020 | 73 | |
| 5 | 2016 | 71 | |
| 6 | 2021 | 63 | |
| 7 | 2020 | 53 | |
| 8 | 2013 | 52 | |
| 9 | 2017 | 43 | |
| 10 | 2018 | 42 | |
| 11 | 2022 | 42 | |
| 12 | 2019 | 40 | |
| 13 | 2011 | 35 | |
| 14 | 2012 | 33 | |
| 15 | 2023 | 31 | |
| 16 | 2021 | 29 | |
| 17 | 2021 | 28 | |
| 18 | 2019 | 28 | |
| 19 | 2019 | 27 | |
| 20 | 2021 | 27 |
About Weijian Sun
Weijian Sun is a scholar working on Molecular Biology, Biomedical Engineering, Oncology, Cancer Research and Immunology, having authored 84 papers that have together received 1.6k indexed citations. Recurring topics across this work include Nanoplatforms for cancer theranostics (16 papers), Cancer-related molecular mechanisms research (8 papers), MicroRNA in disease regulation (7 papers), 3D Printing in Biomedical Research (7 papers), Innovative Microfluidic and Catalytic Techniques Innovation (6 papers), Extracellular vesicles in disease (5 papers), Histone Deacetylase Inhibitors Research (4 papers) and RNA modifications and cancer (4 papers). The work is most often cited by research in Cancer Research (274 citations), Biomaterials (195 citations), Molecular Medicine (62 citations), Biomedical Engineering (482 citations) and Molecular Biology (719 citations). Weijian Sun has collaborated with scholars based in China, United States and Singapore. Frequent co-authors include Xian Shen, Mingdong Lu, Yuanjin Zhao, Pihong Li, Zhiqiang Zheng, Qingfei Zhang, Yongdong Yi, Hui Zhang, Xiaohong Chen and Yingpeng Huang. Their work appears in journals such as Chemical Engineering Journal, International Journal of Biological Macromolecules, Advanced Science, OncoTargets and Therapy and BMC Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.